DP00471: LipoproteinFASTA viewXML view

General information
DisProt:DP00471
Name:Lipoprotein
Synonym(s):Q6QCC2_NEIME
Lipoprotein GNA1870
First appeared in release:Release 3.1 (03/31/2006)
UniProt:Q6QCC2
UniGene: 
SwissProt: Q6QCC2_NEIME
TrEMBL:  
NCBI (GI): 75369663
Source organism:Neisseria meningitidis
Sequence length:274
Percent disordered:13%
Homologues: 


Native sequence

        10         20         30         40         50         60
         |          |          |          |          |          |
MNRTAFCCLS LTTALILTAC SSGGGGVAAD IGAGLADALT APLDHKDKGL QSLTLDQSVR - 60
KNEKLKLAAQ GAEKTYGNGD SLNTGKLKND KVSRFDFIRQ IEVDGQLITL ESGEFQVYKQ - 120
SHSALTAFQT EQIQDSEHSG KMVAKRQFRI GDIAGEHTSF DKLPEGGRAT YRGTAFGSDD - 180
AGGKLTYTID FAAKQGNGKI EHLKSPELNV DLAAADIKPD GKRHAVISGS VLYNQAEKGS - 240
YSLGIFGGKA QEVAGSAEVK TVNGIRHIGL AAKQ



Functional narrative    

Neisseria meningitidis is a human pathogen implicated with sepsis and meningitis in children and young adults. Capsular polysaccharide-based vaccines have been produced for four out of the five major meningococcal serogroups associated with invasive disease (A, C, Y and W135). Unfortunately, the capsular polysaccharide of serogroup B is poorly immunogenic, making this type of vaccine ineffective. As an alternative strategy, reverse vaccinology was exploited for the identification of novel surface-exposed protein antigens to be used in a vaccine formulation against Meningococcus B. Among them, genome-derived Neisseria antigen 1870 (GNA1870) is a lipoprotein of unknown function. In vitro and in vivo assays showed that GNA1870 is expressed on the surface of Meningococcus, is able to elicit good levels of antibodies with bactericidal activity, and induces passive protection in the infant rat model. Three variants of the protein can be distinguished, with levels of sequence similarity ranging from 62.8% between variant 1 and 3, to 74.1% between variant 1 and 2, and 84.7% between variant 2 and 3. Although the three alleles display very low levels of cross-bactericidal response, a vaccine containing representative molecules of the three variants of GNA1870 may be able to protect against all N. meningitidis strains.

Region 1: 120-155

Map of ordered and disordered regions







Note: 'Mouse' over a region to see the start and stop residues. Click on a region to see detailed information.


Region 1
Type:Disordered
Name:immunodominant C-terminal BC domain, N-terminal end
Location:120 - 155
Length:36
Region sequence:

QSHSALTAFQTEQIQDSEHSGKMVAKRQFRIGDIAG

Modification type: Fragment
Native
PDB: 1YS5:A
Structural/functional type: Relationship to function unknown
Functional classes:  
Functional subclasses:  
Detection methods:
  1. Nuclear magnetic resonance (NMR) (298 K; pH: 7; 1.0 mM protein; 20 mM phosphate)

References:
  1. Cantini F, Savino S, Scarselli M, Masignani V, Pizza M, Romagnoli G, Swennen E, Veggi D, Banci L, Rappuoli R. "Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis." J Biol Chem. 2006; 281(11): 7220-7. PubMed: 16407174

Comments:
 



References

  1. Welsch JA, Rossi R, Comanducci M, Granoff DM. "Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine." J Immunol. 2004; 172(9): 5606-15. PubMed: 15100304


If you have any comments or wish to provide additional references to this protein or its disordered region(s), please click here to e-mail us.


Disprot-footer
Contact us